| Literature DB >> 25310577 |
Tiffany-Jane Evans1, Elizabeth Milne2, Denise Anderson2, Nicholas H de Klerk2, Sarra E Jamieson2, Bente A Talseth-Palmer1, Nikola A Bowden1, Elizabeth G Holliday3, Jérémie Rudant4, Laurent Orsi5, Ebony Richardson6, Laura Lavis6, Daniel Catchpoole7, John R Attia8, Bruce K Armstrong9, Jacqueline Clavel5, Rodney J Scott10.
Abstract
Genome wide association studies (GWAS) have established association of ARID5B and IKZF1 variants with childhood acute lymphoblastic leukemia (ALL). Epidemiological studies suggest that environmental factors alone appear to make a relatively minor contribution to disease risk. The polygenic nature of childhood ALL predisposition together with the timing of environmental triggers may hold vital clues for disease etiology. This study presents results from an Australian GWAS of childhood ALL cases (n = 358) and population controls (n = 1192). Furthermore, we utilised family trio (n = 204) genotypes to extend our investigation to gene-environment interaction of significant loci with parental exposures before conception, and child's sex and age. Thirteen SNPs achieved genome wide significance in the population based case/control analysis; ten annotated to ARID5B and three to IKZF1. The most significant SNPs in these regions were ARID5B rs4245595 (OR 1.63, CI 1.38-1.93, P = 2.13×10(-9)), and IKZF1 rs1110701 (OR 1.69, CI 1.42-2.02, p = 7.26×10(-9)). There was evidence of gene-environment interaction for risk genotype at IKZF1, whereby an apparently stronger genetic effect was observed if the mother took folic acid or if the father did not smoke prior to pregnancy (respective interaction P-values: 0.04, 0.05). There were no interactions of risk genotypes with age or sex (P-values >0.2). Our results evidence that interaction of genetic variants and environmental exposures may further alter risk of childhood ALL however, investigation in a larger population is required. If interaction of folic acid supplementation and IKZF1 variants holds, it may be useful to quantify folate levels prior to initiating use of folic acid supplements.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25310577 PMCID: PMC4195717 DOI: 10.1371/journal.pone.0110255
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
SNPs associated with Childhood ALL at P<5×10−8.
| Alleles(A/B) | ALL v Controls | B-ALL (n = 319) vs Controls (n = 1192) | |||||||||
| MAF | |||||||||||
| Typed | rs ID | Chr | Position | Gene (location) | Cases (n = 358) | Controls (n = 1192) | Allelic OR(95% CI) | P | Allelic OR(95% CI) | P | |
| --- | rs4245595 | 10 | 63722895 |
| T/C | 0.46 | 0.34 | 1.63 (1.38–1.93) | 2.13E-09 | 1.86 (1.54–2.25) | 1.21E-10 |
| --- | rs7090445 | 10 | 63721176 |
| T/C | 0.46 | 0.34 | 1.63 (1.37–1.93) | 2.81E-09 | 1.83 (1.51–2.20) | 2.88E-10 |
| --- | rs4948492 | 10 | 63719739 |
| T/C | 0.46 | 0.34 | 1.63 (1.37–1.93) | 2.84E-09 | 1.82 (1.51–2.20) | 2.91E-10 |
| --- | rs7896246 | 10 | 63724390 |
| G/A | 0.46 | 0.34 | 1.61 (1.36–1.91) | 4.63E-09 | 1.81 (1.50–2.19) | 5.11E-10 |
| --- | rs4245597 | 10 | 63725942 |
| A/G | 0.46 | 0.35 | 1.6 (1.35–1.9) | 5.87E-09 | 1.81 (1.50–2.19) | 5.99E-10 |
| --- | rs10821937 | 10 | 63723909 |
| T/C | 0.46 | 0.35 | 1.6 (1.35–1.9) | 6.36E-09 | 1.81 (1.50–2.18) | 6.96E-10 |
| --- | rs10821936 | 10 | 63723577 |
| T/C | 0.46 | 0.35 | 1.6 (1.35–1.9) | 6.36E-09 | 1.81 (1.50–2.18) | 6.95E-10 |
| --- | rs7087507 | 10 | 63745689 |
| A/G | 0.46 | 0.35 | 1.62 (1.37–1.92) | 6.96E-09 | 1.80 (1.50–2.18) | 6.99E-10 |
| --- | rs1110701 | 7 | 50478627 |
| A/G | 0.39 | 0.28 | 1.69 (1.42–2.02) | 7.26E-09 | 1.91 (1.57–2.32) | 8.27E-11 |
| --- | rs9415635 | 10 | 63753482 |
| A/G | 0.46 | 0.34 | 1.6 (1.35–1.89) | 2.17E-08 | 1.76 (1.46–2.12) | 2.96E-09 |
| rs7089424 | rs7089424 | 10 | 63752159 |
| T/G | 0.46 | 0.34 | 1.6 (1.35–1.89) | 2.35E-08 | 1.76 (1.46–2.12) | 3.26E-09 |
| --- | rs10272724 | 7 | 50477213 |
| T/C | 0.37 | 0.26 | 1.67 (1.4–1.99) | 3.71E-08 | 1.90 (1.56–2.31) | 1.93E-10 |
| --- | rs17133807 | 7 | 50477687 |
| G/A | 0.37 | 0.26 | 1.66 (1.39–1.98) | 3.88E-08 | 1.90 (1.56–2.32) | 1.93E-10 |
Genotyped SNPs indicated in this column, dashed entries indicate imputed SNPs.
Allele B is the minor allele for all SNPs in this table.
Odds ratios represent the effect of additional copies of the B (minor allele).
Abbreviations: MAF, Minor Allele Frequency; Chr, Chromosome; OR, Odds Ratio; CI, Confidence Interval; P, P-value; B-ALL, B-cell Acute Lymphoblastic Leukemia.
rs7000234
, rs7018449 and rs6992620. This result, however, was not replicated when interrogated in the French dataset (Table S3 in File S1 and Figure S4 in File S1).Estimates for genetic main effects of variation at rs4132601 and interaction with parental exposures, age and sex for 204 case-trios.
| Genotype-wise Association | |||||||
| Variable Name | Genotype | P | Environmental Exposure Present | Cases: Controls | OR | 95% CI | P |
| Restricted to non-missing questionnaires | |||||||
|
| (GG) | 25∶41∶00 | 2.53 | 1.31–4.91 |
| ||
| (GT) |
| None | 84∶260 | 1.2 | 0.82–1.77 | 0.35 | |
| (TT) (REF) | 95∶311 | 1 | |||||
| Mother alcohol use before pregnancy | |||||||
| GG | Yes | 17∶23 | 3.72 | 1.63–8.50 |
| ||
| GT | 58∶168 | 1.5 | 0.92–2.45 | 0.1 | |||
| TT | 0.18 | 58∶208 | 1 | ||||
| GG | No | 8∶18 | 1.2 | 0.38–3.71 | 0.46 | ||
| GT | 26∶92 | 0.78 | 0.40–1.51 | 0.76 | |||
| TT | 37∶103 | 1 | |||||
| Mother folic acid use before pregnancy | |||||||
| GG | Yes | 12∶14 | 7.34 | 2.23–24.2 |
| ||
| GT | 26∶72 | 2.39 | 1.06–5.40 | 0.04 | |||
| TT |
| 31∶121 | 1 | ||||
| GG | No | 13∶27 | 1.46 | 0.63–3.37 | 0.38 | ||
| GT | 57∶189 | 0.89 | 0.57–1.41 | 0.63 | |||
| TT | 63∶183 | 1 | |||||
| Father smoked during 2 years before pregnancy | |||||||
| GG | Yes | 6∶11 | 1.35 | 0.42–4.36 | 0.61 | ||
| GT | 23∶89 | 0.68 | 0.36–1.29 | 0.24 | |||
| TT |
| 40∶107 | 1 | ||||
| GG | No | 18∶28 | 4.07 | 1.73–9.57 |
| ||
| GT | 55∶151 | 1.84 | 1.08–3.15 | 0.03 | |||
| TT | 47∶181 | 1 | |||||
| Patient sex | |||||||
| GG | Male | 13∶23 | 2.24 | 0.93–5.40 | 0.07 | ||
| GT | 45∶137 | 1.2 | 0.71–2.02 | 0.49 | |||
| TT | 0.904 | 51∶167 | 1 | ||||
| GG | Female | 12∶18 | 2.98 | 1.08–8.19 | 0.03 | ||
| GT | 39∶123 | 1.21 | 0.67–2.16 | 0.53 | |||
| TT | 44∶144 | 1 | |||||
|
| Mean Age (Cases:Controls) | OR | 95% CI | P | |||
| GG | 5.2:5.7 | 0.88 | 0.72–1.07 | 0.2 | |||
| GT | 0.314 | 4.7:5.1 | 0.93 | 0.84–1.04 | 0.2 | ||
| TT | 5.7:5.2 | 1 | |||||
Case numbers reduced from GWAS according to the availability of both, parent genotypes and completed questionnaire; three matched controls per case were theoretically deduced from known parent genotypes.
Referent group was genotype TT for all ORs.
Likelihood ratio test p-value for main genetic effect (2df).
likelihood ratio test p-value for additional interaction (2df) comparing environmental exposure categories.
Abbreviations: OR, Odds Ratio; CI, Confidence Interval; P, P-value.